Previous close | 3.5500 |
Open | 2.9400 |
Bid | 2.7700 |
Ask | 3.0500 |
Strike | 125.00 |
Expiry date | 2024-05-17 |
Day's range | 2.5400 - 3.2300 |
Contract range | N/A |
Volume | |
Open interest | 2.12k |
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergHSBC CEO Quinn Unexpectedly Steps Down After Almost 5 YearsBinance and CZ’s Fortunes Are Set to Grow, Even in JailWall Street Hit by Fed Jitters to Close Wild April: Markets Wrap